Dr. Christiane Simone Querfeld, MD, PhD

Dr. Querfeld practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Querfeld's NPI, 1467772533, was assigned on June 10, 2010. Dr. Querfeld graduated from Univ Cologne- Fac Med in 1994. Dr. Querfeld's California license number on file is A131668.

Dr. Querfeld's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Querfeld's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Dr. Querfeld to 1 more other site, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Querfeld practices. Vendor and product names are available with a free account.

Dermatopathology is Dr. Querfeld's primary specialty in the NPI Registry, under taxonomy code 207ND0900X. Dr. Querfeld is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Querfeld's licenses on file in 3 states: California, New York and Illinois.

Dmand AI lists acne, acute skin infection, cancerous skin growth removal, contact dermatitis, itchy rashes, rash and skin cyst among the conditions Dr. Querfeld treats.

CMS data shows 2,009 Medicare services from Dr. Querfeld across 14 procedure codes in 2024, for 466 Medicare patients. Medicare paid $79,904 for them.

CMS counts 466 Medicare patients who saw Dr. Querfeld in 2024. The largest group is 65 to 74, with 219 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 19% are also on Medicaid. Their average risk score is 2.03, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Querfeld's median patient age at 70, with 47% women.

In 2024, Dr. Querfeld wrote 236 Medicare Part D claims for 60 patients. 70% of them were for generic drugs. CMS names the drug for 155 of them, across 8 drugs with 11 or more claims each, at $387,736 in total drug cost. In 2023, CMS named 61 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Querfeld for performance year 2024, reported as part of a group. Dr. Querfeld accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Querfeld as offering telehealth. CMS counts 91 procedures of removal of skin lesions by Dr. Querfeld, more than 75% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 96 papers to Dr. Querfeld, published from 2010 to 2024. 2021 was the busiest year, with 11. The most frequent topics are Skin Neoplasms, Lymphoma, T-Cell, Cutaneous and Mycosis Fungoides. Dr. Querfeld has published most often in J Am Acad Dermatol. Dr. Querfeld's most frequent co-authors are Steven T. Rosen, MD, Jasmine M. Zain, MD and Melissa P. Pulitzer, MD.

Dmand AI links Dr. Querfeld to 9 clinical trials, 3 of them phase 1 studies. 4 are still active or recruiting. Conditions studied include Mycosis Fungoides, Sezary Syndrome and Lymphoma, T-Cell, Cutaneous. City of Hope Medical Center sponsors the most, 3.

CMS Open Payments shows 184 general payments to Dr. Querfeld from 26 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 67% of the total. Helsinn Healthcare SA paid the most, $42,593.

Dmand AI lists 8 awards for Dr. Querfeld, most recently Scholar in Clinical Research in 2018.

Dr. Querfeld graduated from Univ Cologne- Fac Med in 1994. Dr. Querfeld is a member of AAD.

Dr. Querfeld is in network with 7 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 5. Check the plan with the practice before a visit.